There were no clinically related adjustments as compared to 2011 except for new knowledge and new tips regarding the treatment method with bisphosphonates and denosumab (see section ‘Bisphosphonates and RANKL Antibody Denosumab’).In the case of invasive breast most cancers, no secondary resection has become proposed for various several years on